Financial Performance - The company's revenue for Q1 2023 reached ¥332,570,440.03, representing a 94.81% increase compared to ¥170,717,067.49 in the same period last year[3]. - Net profit attributable to shareholders was ¥130,078,277.07, a significant increase of 386.55% from ¥26,734,954.17 year-on-year[3]. - Basic earnings per share rose to ¥1.11, reflecting a 382.61% increase from ¥0.23 in the same period last year[3]. - The net profit for Q1 2023 was CNY 130,562,704.27, a significant increase from CNY 26,747,582.62 in Q1 2022, representing a growth of approximately 387.5%[18]. - Operating profit for Q1 2023 reached CNY 130,874,430.89, compared to CNY 26,795,582.62 in the same period last year, indicating a substantial increase[18]. - The total comprehensive income for Q1 2023 was CNY 130,562,704.27, compared to CNY 26,747,582.62 in the same quarter last year, showing a growth of approximately 387.5%[19]. Cash Flow and Liquidity - The net cash flow from operating activities was ¥141,897,609.33, up 164.11% from ¥53,725,956.55 in the previous year[3]. - Cash flow from operating activities generated CNY 141,897,609.33 in Q1 2023, compared to CNY 53,725,956.55 in Q1 2022, marking an increase of approximately 163.5%[22]. - Cash and cash equivalents at the end of Q1 2023 were RMB 625,681,712.53, an increase of 45.0% from RMB 431,650,815.29 at the beginning of the year[14]. - Cash and cash equivalents at the end of Q1 2023 amounted to CNY 625,681,712.53, an increase from CNY 605,921,777.86 at the end of Q1 2022[22]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,139,389,690.40, an increase of 8.03% from ¥1,980,363,134.91 at the end of the previous year[3]. - The total assets as of March 31, 2023, were RMB 2,139,389,690.40, compared to RMB 1,980,363,134.91 at the beginning of the year, indicating a growth of 8.0%[16]. - The total liabilities increased to RMB 473,389,339.45 from RMB 457,825,488.23, representing a rise of 3.7%[16]. Research and Development - The company reported a 90.20% increase in R&D expenses, totaling ¥3,201,710.64, due to increased investment in research and development[7]. - Research and development expenses rose to CNY 3,201,710.64 in Q1 2023, up from CNY 1,683,353.92 in Q1 2022, reflecting a year-over-year increase of about 90.3%[18]. Operational Costs - The company experienced a 31.10% rise in main business costs, amounting to ¥188,370,721.20, primarily due to the production commencement of a new facility[7]. - The total operating costs for Q1 2023 amounted to RMB 203,831,933.89, up from RMB 148,586,196.63, reflecting a year-over-year increase of 37.2%[17]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 13,347[10]. Future Outlook - The company plans to continue expanding its market presence and investing in new product development to sustain growth[3]. - There are no significant market expansion or acquisition strategies detailed in the report, indicating a focus on internal growth and financial stability[13]. - The company has no new product or technology developments mentioned in the report, focusing instead on financial performance and asset management[13].
华绿生物(300970) - 2023 Q1 - 季度财报